Lipoprotein(a) in nephrological patients

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 1 endocrinologydiseases
ezetimibe 1 endocrinologydiseasesdrugs
hyperparathyroidism 1 endocrinologydiseases
hyperphosphatemia 1 endocrinologydiseases
rosuvastatin 1 endocrinologydiseasesdrugs
secondary hyperparathyroidism 1 endocrinologydiseases
simvastatin 1 endocrinologydiseasesdrugs
atorvastatin 3 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
atorvastatin 6603 the 4D study which included type 2 diabetics undergoing hemodialysis either treated with 20 mg of atorvastatin or placebo [[18]]. 1233 out of 1255 initial samples were available and measurement of Lp(a) was performed
atorvastatin 10288 CKD incl. Lp(a). * 2.6 mmol/L; # 1.8 mmol/L; § 120 nmol/L; LA = lipoprotein apheresis; ‡ using atorvastatin , simvastatin/ezetemibe, rosuvastatin, or atorvastatin/ezetimibe, and/or PCSK9
atorvastatin 10342 nmol/L; LA = lipoprotein apheresis; ‡ using atorvastatin, simvastatin/ezetemibe, rosuvastatin, or atorvastatin /ezetimibe, and/or PCSK9
ezetimibe 10355 lipoprotein apheresis; ‡ using atorvastatin, simvastatin/ezetemibe, rosuvastatin, or atorvastatin/ ezetimibe , and/or PCSK9
rosuvastatin 10325 mmol/L; § 120 nmol/L; LA = lipoprotein apheresis; ‡ using atorvastatin, simvastatin/ezetemibe, rosuvastatin , or atorvastatin/ezetimibe, and/or PCSK9
simvastatin 10302 * 2.6 mmol/L; # 1.8 mmol/L; § 120 nmol/L; LA = lipoprotein apheresis; ‡ using atorvastatin, simvastatin /ezetemibe, rosuvastatin, or atorvastatin/ezetimibe, and/or PCSK9
Select Disease Character Offset Disease Term Instance
diabetes mellitus 2692 [[6]]. European best practice guidelines further restrict the LDL-C lowering treatment to patients with diabetes mellitus [[7]].In contrast to ESC and EAS, KDIGO recommendations are mainly based on results from the three major
hyperparathyroidism 3412 towards CKD related factors such as hyperphosphatemia, increased calcium-phosphate product, secondary hyperparathyroidism , and a lack of calcification inhibiting factors finally leading to more pronounced media sclerosis
hyperphosphatemia 3346 shifting the dominance of classical cardiovascular (CV) risk factors towards CKD related factors such as hyperphosphatemia , increased calcium-phosphate product, secondary hyperparathyroidism, and a lack of calcification inhibiting
secondary hyperparathyroidism 3402 factors towards CKD related factors such as hyperphosphatemia, increased calcium-phosphate product, secondary hyperparathyroidism , and a lack of calcification inhibiting factors finally leading to more pronounced media sclerosis

You must be authorized to submit a review.